StockData
Heron Therapeutics, Inc. logo

Heron Therapeutics, Inc. (HRTX) stock

HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$0.28−0.00 (-0.74%)

Close on Nov 17, 2026Market cap $53.58MP/E –Yield –

Heron Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Heron Therapeutics's gross margin for the twelve months ending Jun 30, 2026 was 70.1%. For fiscal 2025 it was 73.3%, against 73.2% the year before. The highest annual figure on record is 97.3% in fiscal 2016.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202573.3%+0.1
FY2024Dec 31, 202473.2%+24.5
FY2023Dec 31, 202348.8%−0.3
FY2022Dec 31, 202249.0%+2.3
FY2021Dec 31, 202146.7%−12.5
FY2020Dec 31, 202059.2%+1.4
FY2019Dec 31, 201957.8%−6.7
FY2018Dec 31, 201864.5%−20.6
FY2017Dec 31, 201785.1%−12.2
FY2016Dec 31, 201697.3%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202669.3%−4.2
Q1 FY2026Mar 31, 202669.4%−8.9
Q4 FY2025Dec 31, 202572.6%−2.3
Q3 FY2025Sep 30, 202568.8%−2.4
Q2 FY2025Jun 30, 202573.5%+2.7
Q1 FY2025Mar 31, 202578.3%+2.6
Q4 FY2024Dec 31, 202474.9%+3.8
Q3 FY2024Sep 30, 202471.2%+29.1
Q2 FY2024Jun 30, 202470.8%+34.3
Q1 FY2024Mar 31, 202475.6%+32.6
Q4 FY2023Dec 31, 202371.1%+13.2
Q3 FY2023Sep 30, 202342.1%−2.5
Q2 FY2023Jun 30, 202336.5%−4.9
Q1 FY2023Mar 31, 202343.1%−8.5
Q4 FY2022Dec 31, 202257.9%+10.9
Q3 FY2022Sep 30, 202244.6%−6.6
Q2 FY2022Jun 30, 202241.5%+6.2
Q1 FY2022Mar 31, 202251.6%−2.4
Q4 FY2021Dec 31, 202147.0%−7.4
Q3 FY2021Sep 30, 202151.1%−13.0
Q2 FY2021Jun 30, 202135.3%−25.0
Q1 FY2021Mar 31, 202154.0%−4.2
Q4 FY2020Dec 31, 202054.4%−0.3
Q3 FY2020Sep 30, 202064.1%+4.4
Q2 FY2020Jun 30, 202060.3%−2.7
Q1 FY2020Mar 31, 202058.2%+5.5
Q4 FY2019Dec 31, 201954.8%−5.1
Q3 FY2019Sep 30, 201959.7%−2.1
Q2 FY2019Jun 30, 201962.9%−6.8
Q1 FY2019Mar 31, 201952.7%−20.3
Q4 FY2018Dec 31, 201859.9%−26.8
Q3 FY2018Sep 30, 201861.7%−26.0
Q2 FY2018Jun 30, 201869.7%−18.4
Q1 FY2018Mar 31, 201872.9%+5.6
Q4 FY2017Dec 31, 201786.7%−10.6
Q3 FY2017Sep 30, 201787.7%–
Q2 FY2017Jun 30, 201788.1%–
Q1 FY2017Mar 31, 201767.3%–
Q4 FY2016Dec 31, 201697.3%–

More Heron Therapeutics figures

See a number that looks wrong?